Drugs / IDREBORMILAST
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04863417 | Jun → Sep 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04135560 | Oct 2019 → Apr 2020 | atopic eczema | Pfizer | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06013371 | Jul 2023 → Feb 2025 | rosacea, seborrheic dermatitis | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 2 | NCT05375955 | Sep 2022 → Jul 2023 | atopic eczema, psoriasis | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT05298033 | Sep 2022 → Apr 2024 | vitiligo | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT04664153 | Dec 2020 → Aug 2021 | atopic eczema, psoriasis | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDREBORMILAST | ChEMBL registry synonym — accepted as the source's own label CHEMBL6056273 ↗ |
| Known as | PF-07038124 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04135560 ↗ |
| Action | Inhibit | “the topical phosphodiesterase 4 inhibitor PF-07038124” PMID 38117526 ↗ Feb 2024 |
| Modality | Small molecule | — CHEMBL6056273 ↗ |
| Route | Topical | “PF-07038124 ointment and vehicle (placebo) in Part A following multiple-doses applied topically to healthy participants” NCT04135560 ↗ |